Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial.

JC Jr, Davis; Der Heijde D, Van; J, Braun; M, Dougados; J, Cush; DO, Clegg; A, Kivitz; R, Fleischmann; R, Inman; W, Tsuji

doi:10.1002/art.11325

Public

Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial.

Shared by NobleBlocks on Nov 1, 2003 • 12:00 AM UTC

Authors:

Davis JC Jr

Van Der Heijde D

Braun J

Abstract

Objective To determine the safety and efficacy of etanercept in a multicenter, randomized, placebo-controlled, double-blind trial of adults with moderate to severe active ankylosing spondylitis (AS).Methods Patients (n = 277) were treated with either etanercept 25 mg (n = 138) or placebo (n = 139) s...

Discussions